Where Will Intel Stock Be in 5 Years: Comeback Story or Cautionary Tale?
Key PointsIntel has bought itself time with government and strategic investors, but that doesn’t prove the underlying turnaround is working.
Nasdaq News
Social Security's Trump Bump-Driven 2027 COLA Is on Track to Make History 3 Different Ways
Key PointsThe wait is nearly over, with Social Security’s highly anticipated cost-of-living adjustment (COLA) set to be announced on Oct. 14.
Robinhood CEO Vlad Tenev Says Crypto Will Lead a Surge in Prediction Market Trading Volume. Here's What It Means for Crypto.
Key PointsRobinhood's CEO, Vlad Tenev, is bullish on prediction markets for crypto prices.
If You'd Invested $1,000 in Broadcom's 2009 IPO, Here's How Much You'd Have Today
Key PointsFor IPO investors, annual dividends now exceed their original investment.
How NASA Saved Boeing's Space Program With a New Contract and $359 Million
Key PointsSpaceX plans to retire the Falcon 9 rocket and Crew Dragon spacecraft after 2030.
With Buffett Recently Stepping Back as Chairman, Here's a Look Back at the $1.3 Billion Bet That’s Now Worth $34.7 Billion
Key PointsBuffett invested about $1.3 billion into Coca-Cola stock in the late 1980s and early 1990s.
Grupo Aeroportuario del Sureste, S. A. B. de C. V. - Depositary Receipt Price Target Decreased by 12.97% to $331.12
The average one-year price target for Grupo Aeroportuario del Sureste, S. A. B. de C. V. - Depositary Receipt (NYSE:ASR) (DB:AEDA) has been revised to $331.12 / share, down 12.97% from the prior estimate of $380.45 dated September 13, 2026. These figures represent aggregate analy
AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.
Key PointsThe drug could eventually generate more than $1 billion annually.
Anthropic Could Raise Up to $100 Billion in Its November IPO
Key PointsAnthropic could raise up to $100 billion with its upcoming stock sale, yet that would cover only about 24% of its more fixed infrastructure commitments.
This Dividend King Is 18.5% Below Its All-Time High and Yields 3%. Is This a Real Opportunity or a Value Trap?
Key PointsProcter & Gamble is facing several headwinds, which have weighed on its earnings and share price.
Here Are the 3 Crucial Concepts That Investors Need to Succeed With Cryptocurrency in 2026 and Beyond
Key PointsA cryptocurrency's supply policies are some of the most important factors for its value.
What Is the Stock Market? It's Not a Casino. Here's How I Filter Winners From Losers.
Key PointsShort-term options that are far-out-of-the-money are the "casino corner" of the stock market, but long-term investing is different.
Prediction: This AI Chip Stock Will Be the Biggest Winner of 2027 (Hint: It’s Not Nvidia, AMD, or Broadcom)
Key PointsTSMC is poised to raise chipmaking fees, which could set it up for big gains in 2027.
Intel Was Worth About 28 Times as Much as AMD 10 Years Ago. Now AMD Is Worth About 60% More.
Key PointsIn late September 2016, Intel's market value was around 28 times as big as AMD's.
Looking For a Crypto ETF With Upside Potential? These 3 ETFs Are Worth a Closer Look.
Key PointsThe biggest Bitcoin fund has a habit of bouncing back.
Which Is the Better Dividend ETF for Income Investors: JEPQ or SCHD?
Key PointsThe JPMorgan Nasdaq Equity Premium Income ETF offers exceptional current income.
If You Invest $300 Per Month in the Vanguard Information Technology ETF for 20 Years, Here's What History Says You Could End Up With
Key PointsThe Vanguard Information Technology ETF has produced a total annualized return of more than 17% in the past two decades.
It's Not Just Larger Checks That Matter: This Big 2027 Social Security Change Could Put More Money in Your Pocket
Key PointsSocial Security benefits are expected to increase after the upcoming COLA is applied.
Is a Microsoft Stock Split Coming After 23 Years?
Key PointsMicrosoft's latest stock split was a 2-for-1 split in February 2003, its ninth since going public in 1986.
Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40
The average one-year price target for Turn Therapeutics (NASDAQGM:TTRX) has been revised to $20.40 / share. This is an increase of 24.42% from the prior estimate of $16.40 dated September 11, 2026. These figures represent aggregate analyst targets and do not constitute a recomme
This feed is responsible for generating the rss feed related to the topic latest article
Subscribe to Nasdaq News feed